Pulmonary Hypertension – Current Treatment – Current Treatment: Physician Insights – Pulmonary Arterial Hypertension (US)

Pulmonary arterial hypertension (PAH) treatment in the United States is undergoing notable shifts as physicians increasingly adopt guidelinealigned early combination therapy, driving steady use of ERAs, PDE5 inhibitors, prostacyclinpathway agents, and sGC stimulators across WHO functional classes. Oral combinations remain foundational in earlier stages, while escalation to prostacyclinbased regimens is becoming more routine as symptoms progress, supported by innovations in inhaled delivery and patientfriendly titration systems. The entry of novel mechanisms, most prominently Merck & Co.’s Winrevair (sotatercept), has broadened addon options and introduced meaningful competitive change. Within this broader landscape, idiopathic PAH (IPAH) represents the segment with the fastestevolving treatment behaviors, as specialists favor earlier intensification, closer riskbased adjustments, and therapies that support longterm adherence and functional stability. Despite greater therapeutic choice, unmet need remains significant among patients who do not achieve or maintain lowrisk status, prompting renewed scrutiny of sequencing patterns, switch triggers, and brand differentiation. This report analyzes the dynamics of the IPAH therapy market, with a focus on treatment strategies across all WHO / NYHA functional classes.

QUESTIONS ANSWERED

• What are the drug treatment rates across all WHO / NYHA functional classes?
• Which product attributes do U.S. pulmonologists and cardiologists perceive as most important for the treatment of their PAH patients across all WHO / NYHA functional classes?
• What patient shares does the oral ERA + PDE5i combination therapy garner among PAH patients? What are the factors influencing the uptake?
• What is the criterial for introducing sotatercept to PAH patients? What factors are driving and limiting the uptake of the drug?

CONTENT HIGHLIGHTS

Geographies: United States.

Primary research: Survey of 80 pulmonologists and 20 cardiologists.

Key drugs covered: bosentan, ambrisentan, macitentan, sildenafil, tadalafil, oral treprostinil, inhaled treprostinil, dry-powder inhaled treprostinil, selexipag, parenteral treprostinil, sotatercept, riociguat

PRODUCT DESCRIPTION

Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:

• Understand the treatment landscape for a disease and how physicians make prescribing decisions.
• Evaluate the drivers and obstacles that influence treatment selection.
• Analyze your brand’s performance from the physician perspective to enhance or defend your competitive position.
• Create impactful messaging for physicians by identifying brand differentiators and understanding what motivates prescribing behaviors.